Single-tablet HIV regimen hits safety, efficacy targets

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Once-daily single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide effectively suppresses virological rebound in treatment-experienced HIV-1 infected (TE-HIV) adults.
  • Regimen is noninferior to boosted protease inhibitor (BPI) combined emtricitabine/tenofovir disoproxil fumarate treatment.

Why this matters

  • Once-daily single-table HIV-1 regimens may promote treatment adherence.
  • Darunavir component provides a high genetic barrier to resistance, whereas tenofovir alafenamide is comparable to tenofovir disoproxil fumarate at one-tenth of the dose, decreasing risk for renal toxicity and changes in bone density.
  • Findings also demonstrate utility in adults with history of virological failure on nondarunavir regimens.

Study design

  • Randomized, multicenter, active-controlled, noninferiority, phase-3 (EMERALD) study on TE-HIV adults (study group [SG], n=763; control group [CG; BPI], n=378).
  • Funding: Janssen.

Key results

  • At 48 wk, 2.5% patients of SG and 2.1% of CG had virological rebound (difference, 0.4%; Pnoninferiority<.0001>
  • The cumulative virological rebound rate in SG vs CG was 1.9% vs 0.8% (difference, 1.1%; P<.0001>
  • Viral load
  • No significant difference seen in time to virological rebound between groups (P=.824).
  • Discontinuations related to adverse events (each, 1%) and grade 3-4 adverse events were similar (7% in SG vs 8% in CG).

Limitations

  • Open-label study.

Coauthored with Chitra Ravi, M.Pharm